Agile Therapeutics, Inc. (AGRX) News

Agile Therapeutics, Inc. (AGRX): $0.32

0.02 (-6.74%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Filter AGRX News Items

AGRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGRX News Highlights

  • AGRX's 30 day story count now stands at 2.
  • Over the past 20 days, the trend for AGRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest AGRX News From Around the Web

Below are the latest news stories about AGILE THERAPEUTICS INC that investors may wish to consider to help them evaluate AGRX as an investment opportunity.

Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement

The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in President Biden’s June 2023 Executive Order Implementation of the Committee’s Recommendation Could Potentially Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women PRINCETON, N.J.,

Yahoo | December 12, 2023

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel ...

Yahoo | November 22, 2023

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58. Operator: Good morning, and welcome to the Agile Therapeutics Third Quarter 2023 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the […]

Yahoo | November 10, 2023

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agil

Yahoo | November 9, 2023

Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023

Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Third Quarter

Yahoo | October 26, 2023

Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to the Company’s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq Listing Rule 5635(c)(4), the award was approved by the Company's Compensation Committee and made as a material inducement to Mr. Coiante’s entry into employment with the Company. In connection with the comme

Yahoo | October 4, 2023

Why Shares of Agile Therapeutics Jumped This Week

Shares of Agile Therapeutics (NASDAQ: AGRX) were up more than 23% for the week as of 3 p.m. on Thursday, according to data provided by S&P Global Market Intelligence. The stock got a boost late last week when it got an upgrade from analysts at Maxim Group with a buy rating and a price target of $5. It also helps that the stock appears to have avoided the threat of being delisted from the Nasdaq for now.

Yahoo | September 28, 2023

Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group

PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. ...

Yahoo | September 28, 2023

Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. Details on the Company presentation are as follows: Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Wednesday, Sep

Yahoo | September 5, 2023

Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter

On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses.

Yahoo | August 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!